Ipsita Roymoulik Partner, CMC

Ipsita has a PhD from the University of Michigan and brings 22 years of CMC, Quality, and Compliance expertise supporting clinical development of oligonucleotide, RNA and cell therapy drugs as a Partner at the Firm leading the CMC, Quality, and Compliance Department.

Prior to joining Y Innovations, Ipsita worked at SQZ Biotechnologies Company as the Senior Vice President of CMC & Quality. During her tenure, Ipsita enabled adoption of rapid technologies to yield high cell therapy manufacturability (100%), full release of cell therapy product in 5-days and administration of 60+ batches of autologous product across 20 domestic/international clinical sites for 3 programs. Previously, Ipsita served as the Director of Analytical Development at Moderna Therapeutics where she pioneered platform CMC approaches for the first 10 INDs and additionally initiated quality control and quality assurance functions for the company. Ipsita also supported and advised multiple clients on cutting-edge analytical technologies for over a decade at Nitto Denko Avecia, the world’s leading cGMP Oligonucleotide CDMO. For her contributions to the field, Ipsita was a 2021 Google Venture Impact List honoree, out of 300+ GV portfolio submissions, for making a difference to her company’s culture, innovation and growth.